Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Damien Earl

Neurology Canton, OH Medical Doctor

NPI 1265774566 CMS profile 4222760

4048 Dressler Rd Nw Ste 100, Canton, OH 44718

Open in the dashboard

General payments

$7,729

390 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Damien Earl of Canton, OH is reported in the CMS Open Payments database as having received $7,729 across 390 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,192 68
2024 General $1,117 61
2023 General $855 51
2022 General $1,265 65
2021 General $1,219 65
2020 General $1,059 46
2019 General $1,022 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Damien Earl
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Damien Earl were reported at $1,192. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Damien Earl Neurology median Middle half National median
2019 $1,022 $474 $118–$2,177 $163
2020 $1,059 $367 $82–$2,309 $114
2021 $1,219 $438 $104–$2,547 $132
2022 $1,265 $442 $103–$2,388 $149
2023 $855 $464 $119–$2,312 $160
2024 $1,117 $468 $119–$2,323 $164
2025 $1,192 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,130 148 payments
  2. Genzyme Corporation $543 16 payments
  3. UCB, Inc. $422 18 payments
  4. SK Life Science, Inc. $421 18 payments
  5. Teva Pharmaceuticals USA, Inc. $408 16 payments
  6. Alexion Pharmaceuticals, Inc. $405 10 payments
  7. ACADIA Pharmaceuticals Inc $347 17 payments
  8. Horizon Therapeutics plc $247 6 payments
  9. E.R. Squibb & Sons, L.L.C. $220 7 payments
  10. Novartis Pharmaceuticals Corporation $208 12 payments
  11. Other $2,377 122 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,652 389 payments
  2. Education $77 1 payment
Products named General payments · program years 2019–2025
  1. QULIPTA $1,056 81 payments
  2. UBRELVY $1,054 64 payments
  3. BOTOX $547 50 payments
  4. AUBAGIO $402 10 payments
  5. AUSTEDO $348 11 payments
  6. Briviact $331 14 payments
  7. NUPLAZID $288 13 payments
  8. Soliris $259 7 payments
  9. UPLIZNA $247 6 payments
  10. NURTEC ODT $230 7 payments
  11. Other $3,433 179 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 90 drugs

Part D claims

6,387

Median for Neurology: 833

Drug cost

$494,660

Median for Neurology: $202,670

Branded share of claims

22.9%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 62 $71,687
Emgality Pen Galcanezumab-Gnlm Brand 52 $36,589
Botox Onabotulinumtoxina Brand 26 $33,445
Qulipta Atogepant Brand 31 $32,951
Aimovig Autoinjector Erenumab-Aooe Brand 36 $31,956
Keppra Levetiracetam Brand 18 $27,765
Levetiracetam Generic 672 $24,744
Ubrelvy Ubrogepant Brand 20 $18,802
Glatiramer Acetate Generic 13 $18,347
Lamictal Lamotrigine Brand 12 $13,286

The 10 drugs with the highest cost, of 90 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$196,629

Of which drugs: $73,161

Medicare patients

734

Average age 71

Services billed

35,669

406 women, 328 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 51%
Depression 37%
Diabetes 31%
Ischemic heart disease 28%
Chronic kidney disease 27%
Heart failure 19%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $171
$171 20 —
NUPLAZID
  • ACADIA Pharmaceuticals Inc $161
$161 — —
BOTOX
  • AbbVie, Inc. $145
$145 26 —
QULIPTA
  • AbbVie, Inc. $129
$129 31 —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $100
$100 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

390 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record